Thursday, November 19, 2026 Vol. I · No. 7
Health · Via The Hill

The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

Image: The Hill

It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

This is a brief. The reporting belongs to The Hill — read the complete story, with full context and credits, at the source.

Read the full story at The Hill ↗

thehill.com

More from the Health desk